EUDA Health Holdings Limited (NASDAQ:EUDA) Short Interest Update

Posted by on May 29th, 2026

EUDA Health Holdings Limited (NASDAQ:EUDA – Get Free Report) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 20,394 shares, a decline of 76.6% from the April 30th total of 87,001 shares. Based on an average trading volume of 53,985 shares, the short-interest ratio is presently 0.4 days. Approximately 0.8% of the shares of the stock are short sold.

EUDA Health Stock Down 3.8%

EUDA stock traded down $0.71 during trading on Friday, hitting $18.06. The company had a trading volume of 3,762 shares, compared to its average volume of 81,763. The firm has a 50-day moving average price of $11.39 and a 200-day moving average price of $27.91. EUDA Health has a 12 month low of $5.26 and a 12 month high of $86.00. The stock has a market cap of $54.00 million, a price-to-earnings ratio of -7.53 and a beta of 0.56.

EUDA Health (NASDAQ:EUDA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.76. The company had revenue of $1.92 million during the quarter, compared to the consensus estimate of $3.90 million. Equities analysts expect that EUDA Health will post 1.6 EPS for the current year.

Analyst Upgrades and Downgrades

EUDA has been the subject of a number of research analyst reports. Greenridge Global cut their target price on shares of EUDA Health from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Weiss Ratings cut shares of EUDA Health from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Finally, Zacks Research upgraded shares of EUDA Health from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $55.00.

Get Our Latest Stock Report on EUDA Health

Institutional Inflows and Outflows

A hedge fund recently raised its stake in EUDA Health stock. Citadel Advisors LLC increased its stake in EUDA Health Holdings Limited (NASDAQ:EUDA – Free Report) by 57.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,631 shares of the company’s stock after purchasing an additional 16,321 shares during the period. Citadel Advisors LLC owned 0.12% of EUDA Health worth $78,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 4.35% of the company’s stock.

About EUDA Health

(Get Free Report)

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.

Featured Articles

Receive News & Ratings for EUDA Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EUDA Health and related companies with MarketBeat.com's FREE daily email newsletter.